Can Fite Biopharma Ltd (CANF) Short Interest Update
Can Fite Biopharma Ltd (NYSEAMERICAN:CANF) was the recipient of a large decline in short interest during the month of February. As of February 15th, there was short interest totalling 487,565 shares, a decline of 29.5% from the January 31st total of 691,907 shares. Based on an average daily trading volume, of 120,869 shares, the short-interest ratio is presently 4.0 days.
A hedge fund recently bought a new stake in Can Fite Biopharma stock. Meitav Dash Investments Ltd. acquired a new position in shares of Can Fite Biopharma Ltd (NYSEAMERICAN:CANF) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 155,000 shares of the biotechnology company’s stock, valued at approximately $240,000. Meitav Dash Investments Ltd. owned about 0.93% of Can Fite Biopharma at the end of the most recent reporting period. Institutional investors and hedge funds own 5.12% of the company’s stock.
Can Fite Biopharma (NYSEAMERICAN:CANF) opened at $1.88 on Thursday. The firm has a market cap of $28.80, a PE ratio of 6.24 and a beta of 1.79. Can Fite Biopharma has a 52 week low of $1.24 and a 52 week high of $2.75.
CANF has been the topic of several recent analyst reports. Maxim Group set a $7.00 price objective on shares of Can Fite Biopharma and gave the stock a “buy” rating in a research note on Monday, December 18th. HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of Can Fite Biopharma in a research note on Thursday, February 1st.
WARNING: This report was first published by Watch List News and is owned by of Watch List News. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://www.watchlistnews.com/can-fite-biopharma-ltd-canf-short-interest-update/1897572.html.
About Can Fite Biopharma
Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases.
Receive News & Ratings for Can Fite Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can Fite Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.